Altimmune diskutieren
Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at B. Riley from $20.00 to $18.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at UBS Group AG from $26.00 to $24.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune (NASDAQ:ALT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Neueste Beiträge
Roth_Mkm in Discuss Vicor Corp.